February 20, 2025 Vivli and RDCA-DAP Present: Data Platform Partnerships to Promote Rare Disease Data Sharing Join Julie Wood, Chief Operating Officer at Vivli, for an engaging webinar, Thursday, February 20, where she’ll discuss...
January 21, 2025 Save the Date: CGIC Returns to D.C. this September We are thrilled to invite you to the 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC)...
January 7, 2025 Inclusion in neurological research: empowering people living with neurological diseases The value of involving people living with diseases in the research process is increasingly recognized...
December 12, 2024 Investigating item response theory model performance in the context of evaluating clinical outcome assessments in clinical trials Item response theory (IRT) models are an increasingly popular method choice for...
November 27, 2024 A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials...
December 1, 2024 Advancing rare disease measurement through the Rare Disease Clinical Outcome Assessment Consortium Naomi Knoble, and Lindsey T. Murray on behalf of the Rare Disease Clinical Outcome Assessment Consortium. View all authors and aff
November 5, 2024 C-Path Scientific Directors Belmonte, Kosinski to Present at 20th IDS Congress Paul Belmonte, C-Path’s Scientific Director, T1D Consortium, and Luke Kosinski, Director, Quantitative Medicine, will present...
September 30, 2024 TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction...
October 8, 2024 Flexible approaches to eCOA administration in clinical trials: The site perspective Estelle Haenel, Celeste A. Elash, Katie Garner, Megan Turner, Scottie KernAbstract Electronic Clinical Outcome Assessment (eCOA) C
October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
